OPTN Stock Quote
| Symbol: | OPTN |
|---|---|
| Quote: | 9.44 |
| Change: | +0.02 |
| Change %: | +0.20% |
| High: | 9.47 |
| Low: | 9.41 |
| Open: | 9.41 |
|---|---|
| Volume: | 5,014 |
| 52 Week: | 4.82-20.02 |
| P/E Ratio: | -4.45 |
| EPS: | -2.12 |
| Market Cap: | 95.59 M |
Company Report
OptiNose, Inc. is a specialty pharmaceutical company dedicated to advancing innovative treatments for patients under the care of ear, nose, throat, and allergy specialists across the United States. Central to its portfolio is XHANCE, a therapeutic product leveraging its proprietary exhalation delivery system (EDS). This system delivers a topically-acting corticosteroid specifically designed for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE is currently undergoing Phase IIIb clinical trials for the treatment of chronic sinusitis, underscoring OptiNose's commitment to addressing unmet medical needs in sinus-related disorders.
Additionally, OptiNose markets Onzetra Xsail, another pivotal product utilizing a powder EDS device. The company continues to innovate with OPN-019, an ongoing development combining a liquid EDS device with an antiseptic agent, aimed at expanding therapeutic options for patients.
OptiNose has entered into strategic partnerships to enhance its market reach and product offerings. This includes a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail, positioning the company to leverage complementary expertise in delivering effective migraine relief solutions. Furthermore, a collaboration with Inexia Limited focuses on developing, manufacturing, importing, and selling products incorporating orexin receptor agonists and positive modulators. These efforts underscore OptiNose's commitment to exploring novel treatments for a spectrum of human diseases and conditions associated with orexin receptor modulation.
Founded in 2000 and headquartered in Yardley, Pennsylvania, OptiNose, Inc. continues to drive innovation in the field of specialty pharmaceuticals, aiming to improve patient outcomes and quality of life through its distinctive delivery technologies and therapeutic advancements.
OPTN EPS Chart
OPTN Revenue Chart
OPTN Profile
| Exchange: | NASDAQ |
|---|---|
| Beta: | -0.885 |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Employees: | 127 |
| IPO Date: | Oct 13, 2017 |
OPTN News
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per sh... 14 days ago |
OptiNose (OPTN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.35 per share a year ago. 1 months ago |
The average of price targets set by Wall Street analysts indicates a potential upside of 143.1% in OptiNose (OPTN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 1 months ago |
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per sh... 1 months ago |
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio. 1 months ago |
Analyst Ratings